Lace M. Riggs, M.A.
Graduate Student Neuroscience
|
Education
M.A. in Experimental Psychology, California State University, San Bernardino, CA B.A. in Biological Psychology, California State University, San Bernardino, CA Current Projects Examining the neurophysiological mechanisms of rapid antidepressant efficacy. Other Research Interests Neurodevelopment, addiction, epigenetics, research ethics, health disparities, diversity. Contact Information Email: lacemriggs[at]som.umaryland.edu Phone: (410) 706-6799 |
Research Description
I earned a B.A. in Biological Psychology and an M.A. in Experimental Psychology from California State University. There, I studied risk factors associated with enhanced susceptibility to adolescent depression, as well as the long-lasting neurobehavioral consequences of early antidepressant treatment. In order to investigate novel antidepressant mechanisms of action, I joined the laboratory of Dr. Todd D. Gould at the University of Maryland School of Medicine, where I am currently earning a Ph.D. in Neuroscience in the Graduate Program in Life Sciences. The goal of my dissertation research is to use biochemical, electrophysiological, and photometric approaches to investigate the mechanisms underlying the rapid antidepressant actions of the ketamine metabolite, (2R,6R)-hydroxynorketamine.
I earned a B.A. in Biological Psychology and an M.A. in Experimental Psychology from California State University. There, I studied risk factors associated with enhanced susceptibility to adolescent depression, as well as the long-lasting neurobehavioral consequences of early antidepressant treatment. In order to investigate novel antidepressant mechanisms of action, I joined the laboratory of Dr. Todd D. Gould at the University of Maryland School of Medicine, where I am currently earning a Ph.D. in Neuroscience in the Graduate Program in Life Sciences. The goal of my dissertation research is to use biochemical, electrophysiological, and photometric approaches to investigate the mechanisms underlying the rapid antidepressant actions of the ketamine metabolite, (2R,6R)-hydroxynorketamine.
funding
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship
NIH National Institute of Mental Health (NIMH), F31-MH123066
“Synaptic mechanisms underlying the rapid antidepressant properties of the (2R,6R)-hydroxynorketamine metabolite.”
Training Program in Integrative Membrane Biology, UMSOM
NIH National Institute of General Medical Sciences (NIGMS), T32-GM008181
Student of Merit Award, Training Program in Neuroscience, UMSOM
NIH National Institute of Neurological Disorders and Stroke (NINDS), T32-NS063391
Meyerhoff Graduate Fellowship Program, Initiative for Maximizing Student Development, UMD
NIH National Institute of General Medical Sciences (NIGMS), R25-GM055036
NIH National Institute of Mental Health (NIMH), F31-MH123066
“Synaptic mechanisms underlying the rapid antidepressant properties of the (2R,6R)-hydroxynorketamine metabolite.”
Training Program in Integrative Membrane Biology, UMSOM
NIH National Institute of General Medical Sciences (NIGMS), T32-GM008181
Student of Merit Award, Training Program in Neuroscience, UMSOM
NIH National Institute of Neurological Disorders and Stroke (NINDS), T32-NS063391
Meyerhoff Graduate Fellowship Program, Initiative for Maximizing Student Development, UMD
NIH National Institute of General Medical Sciences (NIGMS), R25-GM055036
selected publications
Riggs LM and Gould TD (2021). Ketamine and the future of rapid-acting antidepressants. Annual Review of Clinical Psychology, PMID: 33561364.
Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD (2020). (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology, PMID: 31216563.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018). Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews, 70(3):621-660. PMID: 29945898.
For full list, please visit:
Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD (2020). (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology, PMID: 31216563.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018). Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews, 70(3):621-660. PMID: 29945898.
For full list, please visit:
|
|
